Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07101822 | A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER(BRAVA PENILE) | not yet recruiting | Phase 2 | 42 | Hospital Israelita Albert EinsteinOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05896371 | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy(PRODIGY-1) | not yet recruiting | Phase 1 / Phase 2 | 500 | CHU de Quebec-Universite Laval |
| 0 |
| Mar 30, 2025 |
| clinicaltrials |
| NCT06890832 | A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | not yet recruiting | Phase 2 | 75 | Jina Pharmaceuticals Inc.INDUSTRY | 0 | Mar 24, 2025 | clinicaltrials |
| NCT06827080 | Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 15 | Zhengguo ChenOTHER | 0 | Feb 14, 2025 | clinicaltrials |
| NCT06783153 | Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients | not yet recruiting | Phase 1 / Phase 2 | 80 | Mansoura UniversityOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT06271551 | Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy(ESTRACISE) | not yet recruiting | Phase 2 | 310 | Central Finland Hospital DistrictOTHER | 0 | Feb 21, 2024 | clinicaltrials |
| NCT04176081 | Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer(SChLAP/IDC) | not yet recruiting | Phase 2 | 208 | University Health Network, TorontoOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06129851 | Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer | not yet recruiting | Phase 2 | 90 | University of Kansas Medical CenterOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05778097 | Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)(ARES) | not yet recruiting | Phase 2 | 103 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05717582 | Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment(CHAMPION) | not yet recruiting | Phase 2 | 47 | Fudan UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05373316 | Addition of a Focal Boost in External Beam Radiotherapy for Locally Advanced Prostate Cancer by Online Adaptive MR-guided Radiotherapy(AFFIRM) | not yet recruiting | Phase 2 | 95 | Radboud University Medical CenterOTHER | 1 | Nov 7, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2025source: clinicaltrials